Vontobel Holding Ltd. Sells 5,460 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vontobel Holding Ltd. trimmed its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,804 shares of the biopharmaceutical company's stock after selling 5,460 shares during the quarter. Vontobel Holding Ltd.'s holdings in Alnylam Pharmaceuticals were worth $424,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in ALNY. Jennison Associates LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $61,160,000. Strategic Financial Concepts LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $41,529,000. Eventide Asset Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company's stock worth $61,698,000 after buying an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC increased its position in Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock worth $37,684,000 after acquiring an additional 135,829 shares during the period. Finally, Telemark Asset Management LLC bought a new position in Alnylam Pharmaceuticals during the third quarter worth $27,503,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,548 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 81,356 shares of company stock valued at $22,498,551. Corporate insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, February 14th. Scotiabank cut their target price on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a research report on Friday, February 14th. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Barclays increased their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an "overweight" rating in a research note on Friday, November 1st. Finally, Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $299.48.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded down $0.41 during trading on Friday, reaching $250.59. The company's stock had a trading volume of 653,580 shares, compared to its average volume of 693,794. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The business's 50-day moving average price is $254.04 and its 200-day moving average price is $263.12. The firm has a market cap of $32.44 billion, a PE ratio of -115.48 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.